Medicine Hunter Inc. Founder, Chris Kilham, shares his thoughts on the future cultivation of psychoactive plants and their healing potential on a larger scale
Similar Posts
MindMed Nasdaq Uplisting STOCK PREDICTIONS // How Far will MindMed Go? [MMED/ MMEDF]
Here are my MindMed NASDAQ uplisting STOCK PREDICTIONS! MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.
On the day the news was announced, MMED and MMEDF gained 65.26% , rising from $2.13 to a day high of to $3.57 Though in the last few days the price had fallen, it was still up by 30.86% over the past 2 weeks. MindMed volume increased on the last day, in total, 14 million more shares were traded that the day before. This giant bump brought a lot of MindMed stock speculation which is why we’re making this episode.
Where does MindMed go from here on? MMED / MNMD is still just at the beginning of their long-term growth trajectory so we could only do our due diligence while speculating.
Some speculate that some investors might feel inclined to take profits, which is absolutely understandable. But will they take profits right away or wait for the MNMD price to go ballistic or take profits right away? What will happen to the MindMed stock when/if the do?
Others speculate that the uplisting event might create a FOMO movement which could more than 3X the stock’s price which could create a larger FOMO wave and bring MindMed’s stock price to a similar level to Compass Pathways who’s market cap is very close to MindMed’s.
On this channel, we have been repeatedly saying that investing in the psychedelic industry and specifically in Mindmed should be a long-term play and that the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval. So….
In this segment, we’ll discuss FOUR possible cases:
Timestamps:
0:00 – Intro
4:17 – Worst Case
7:48 – Probable Case
9:57 – #WINNING CASE
11:58 – APES TOGETHER STRONG CASE
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNasdaq #MindMedstock
Interview with Trevor Millar, Advisor, NeonMind Biosciences
In our conversation with Trevor, we have the opportunity to discuss some of the psychedelic-based treatments NeonMind is currently focused on developing to help tackle obesity. Obesity is one of the more prevalent health conditions today affecting millions of individuals worldwide. The World Health Organization has claimed that obesity has reached epidemic proportions globally with at least 2.8 million people dying each year as a result of being overweight or obese.
Psychedelic Stocks in the Short-Term: Expectations, Catalysts, Risks and Reward
When it comes to investing in psychedelic stocks such as MindMed (MNMD, MMED), Compass Pathways (CMPS), atai Life Sciences (ATAI), Cybin (CYBN) and more, even if we have a solid long term thesis, the short term is very volatile.
To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
PS: THIS IS NOT INVESTING ADVICE, JUST MY OPINION.
In this video, I will discuss what to look out for, both the positives and the negatives, in the coming months. What are the catalysts? What are the risks?
The main thing to understand, is that the market cares more about short term profit than it does long term indicators. Right now, we are seeing psychedelic medicine clinical trials showing fantastic results, but we should not expect the market to react until we are closer to commercialization.
There are also many macro risks to be aware of, and general all around volatility. But we need to remember, short term swings do not affect the long-term thesis.
Links:
Awakn Phase 2 Ketamine Therapy for Alcohol Use Disorder:
https://psychedelicspotlight.com/ketamine-trial-alcohol-use-disorder-promising-results-awakn-life-sciences/
MAPS Phase 3 MDMD for PTSD Trial
https://psychedelicspotlight.com/first-phase-3-trial-mdma-assisted-therapy-ptsd/
Compass Pathways Phase 2b Psilocybin for Depression Trial
https://psychedelicspotlight.com/compass-pathways-largest-psilocybin-therapy-trial-ever-depressive-symptoms-rapidly-reduce/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#PsychedelicStocks #MindMed #Cybin
MindMed’s Patent STRATEGY & WHY Haven’t We Covered It YET? (MMED/ MNMD)
MindMed’s Patent STRATEGY & WHY Haven’t We Covered It YET? (MMED/ MNMD)
Patents and IP are important because it allows companies to protect their innovations and re-coup sunk costs into research and development by giving them a set period of time that only they can profit from any inventions they developed.
Given the importance of patents, some people have reached out and have asked why I haven’t talked about MindMed’ patents more.
For example, if you go to their Investors deck, you will see that MindMed, (MMED: NEO), (MNMD : NASDAQ), has 45+ different patent applications. We definitely haven’t done 45 videos on the matter. And that is because we actually don’t know what most of these patent applications are!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#mindmed #mmed #mnmdstock
Insights Into the First Psychedelic-Assisted Therapy Guidelines With Hadas Alterman
We also dive into the significance of the first-ever professional practice guidelines for psychedelic-assisted therapy co-published by APPA and BrainFutures. These guidelines are shaping the future of psychedelic therapy and ensuring its safety and effectiveness.
A Misnomer in Mushrooms: The Jedi Mind Fuck Strain
Come discover the world of the enigmatic Jedi Mind Fuck strain. Is it a significantly more potent strain or is it all hearsay?